导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.68% | 1073/4773 |
| 近一周 | -0.17% | 954/5465 |
| 近一月 | -1.24% | 1075/5421 |
| 近一季 | -11.12% | 3869/5231 |
| 近半年 | -3.18% | 2418/4920 |
| 近一年 | 9.09% | 1239/4394 |
| 近两年 | 96.02% | 665/2954 |
| 近三年 | 46.36% | 632/2253 |
| 成立以来 | 209.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.08% 585/4961 |
17.31% 1475/5312 |
- - |
- - |
| 2025 | 36.40% 950/4813 |
5.77% 735/3635 |
5.40% 596/4076 |
22.16% 1680/4524 |
0.16% 2171/4813 |
| 2024 | 3.48% 1925/3463 |
-6.57% 2064/2808 |
-7.84% 2133/3014 |
14.37% 1989/3129 |
5.08% 642/3463 |
| 2023 | -2.24% 566/2656 |
10.98% 355/2280 |
-1.33% 474/2385 |
-8.16% 1671/2515 |
-2.79% 535/2655 |
| 2022 | -13.18% 318/2207 |
-12.46% 615/1919 |
8.02% 400/2016 |
-8.75% 223/2113 |
0.62% 1477/2208 |
| 2021 | 31.64% 63/1822 |
0.91% 271/1255 |
15.84% 220/1330 |
5.48% 270/1466 |
6.76% 204/1822 |
| 2020 | 33.78% 449/1250 |
3.44% 119/1028 |
23.79% 186/1067 |
5.93% 888/1164 |
-1.38% 1103/1184 |
| 2019 | 32.52% 447/1092 |
28.49% 308/739 |
-4.56% 423/788 |
-0.66% 604/850 |
8.78% 290/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信中证1000指数增强C VS. 长安沪深300非周期A(740101) |